CorMedix Inc. (CRMD) intrinsic value & 10-year financials
CorMedix Inc. (CRMD) has a Graham intrinsic value of $67.76 per share. At $7.26 on Oct 17, 2026, the stock trades 89% below that value. Over the last 10 fiscal years revenue grew 123.5% a year to $311.7M, with an average return on invested capital of -235.7%.
- Graham intrinsic value
- $67.76
- Share price (Oct 17, 2026)
- $7.26
- Price vs Graham value
- 89% below
- Market cap
- $583.0K
- Revenue (FY2025)
- $311.7M
- Revenue growth (10-yr CAGR)
- 123.5%
- ROIC (10-yr avg)
- -235.7%
- Free cash flow (FY2025)
- $172.8M
CRMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $311.7M | $163.1M | $2.04 | $172.8M | 48.2% | 97.6% |
| FY2024 | $43.5M | -$17.9M | -$0.30 | -$50.7M | -51.4% | -58.1% |
| FY2023 | — | -$46.3M | -$0.91 | -$38.7M | — | -234.1% |
| FY2022 | $65.4K | -$29.7M | -$0.74 | -$24.6M | -46819.9% | -262.7% |
| FY2021 | $190.9K | -$28.2M | -$0.75 | -$22.6M | -15417.5% | -416.9% |
| FY2020 | $239.2K | -$22.0M | — | -$22.1M | -11378.4% | -418.3% |
| FY2019 | $283.3K | -$16.4M | — | -$15.1M | -7416.3% | -220.1% |
| FY2018 | $429.8K | -$26.8M | — | -$23.7M | -6250.4% | -442.5% |
| FY2017 | $329.3K | -$33.0M | — | -$28.7M | -9997.4% | -264.0% |
| FY2016 | $224.1K | -$24.6M | — | -$22.3M | -11048.8% | -138.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CorMedix Inc. is a consistent compounder, expanding top-line revenue at 123.5% annually over the past decade.
CorMedix Inc. has historically struggled to out-earn its cost of capital, averaging just -12.1% ROIC.
CorMedix Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CorMedix Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $67.76 per share.